A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCL
NCT06573645
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
428
Enrollment
OTHER
Sponsor class
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
DRUG:
Rituximab
Sponsor
Xia Yi